YOUR GO-TO INTELLIGENCE RESOURCE FOR THE SCHOLARLY PUBLISHING INDUSTRY

Wiley and OpenEvidence have announced a strategic partnership to integrate Wiley’s scientific and medical content into the OpenEvidence medical AI platform. Through the partnership, physicians using OpenEvidence at the point of care can access content from hundreds of Wiley peer-reviewed journals and resources covering major medical specialties to support clinical decision-making.

The announcement states that medical knowledge doubles approximately every 73 days and that historically published research has taken an average of 17 years to reach clinical practice. According to the release, enabling physicians to make point-of-care decisions based on current scientific evidence requires both capable AI systems and reliable scientific content.

OpenEvidence is described as operating on a principle referred to as “gold in, gold out,” which refers to models trained on peer-reviewed medical literature rather than open internet sources. According to the announcement, answers generated by the platform are grounded in sources that physicians can review and verify. By joining OpenEvidence’s existing network of content partners, Wiley expands the body of scientific literature available within the platform.

Under the agreement, Wiley will license a portfolio of scientific and medical content to OpenEvidence. The portfolio includes the Cochrane Database of Systematic Reviews, which the release describes as a source of evidence syntheses widely used to inform clinical guidelines, and Cochrane Clinical Answers, which provides clinical insights derived from Cochrane reviews.

The portfolio will also include more than 400 Wiley journals and books, including medical references such as Holland-Frei Cancer Medicine, Rook's Dermatology Handbook, and Yamada's Textbook of Gastroenterology. According to the announcement, the material spans specialties including cardiology, endocrinology, geriatrics, hematology, internal medicine, neurology, obstetrics, oncology, psychiatry, and rheumatology.

The release states that this content will appear within OpenEvidence’s evidence layer and will be cited with the same transparency. According to the announcement, the platform is used by more than 40 percent of physicians in the United States.

For clinicians, the release states that the partnership expands access to peer-reviewed evidence directly within the point-of-care workflow. The announcement also notes that rare or complex clinical questions often require rapid access to reliable evidence and that expanding the literature available in the platform increases the range of clinical queries that return source-cited answers. The companies stated that the partnership may support additional collaboration opportunities, including expanded society relationships, connections across networks, global expansion, and other healthcare and life sciences use cases.